June 3, 2020
WellDoc's BlueStar chronic disease-management tool has picked up another 510(k) FDA clearance that will allow it to support adult Type 2 diabetes patients using long-acting basal insulin. The feature was announced by WellDoc this morning, but cleared by the agency in April, according to a listing on its website.
The new capability takes the form of a new program within the prescription BlueStar...
March 12, 2020
Together in perfect harmony. Dexcom and Welldoc have kicked off a new collaboration that will provide Dexcom G6 continuous glucose monitor users with data-analysis insights from Welldoc's digital diabetes management product, BlueStar. These insights include information on how lifestyle factors such as activity, nutrition, sleep and medication adherence are affecting a user's glucose levels.
November 5, 2019
Type 1 diabetes management and CGM integration are now on the table for WellDoc’s BlueStar, a management platform well known for being the first mobile health product to secure reimbursement as a diabetes therapy.
Thanks to a new FDA clearance, the company’s seventh, BlueStar will include integrated glucose level insights related to food, medication and activity that are based on the data from...
July 9, 2018
WellDoc has expanded its BlueStar digital diabetes management platform to include a weight loss feature and a feature for those with both diabetes and hypertension. A standalone product for hypertension is also coming from the company later this year.
“The American Diabetes Association reports that nearly one in three American adults has hypertension, and two in three people with diabetes have...
January 11, 2018
Correction: A previous version of this story mistated the projected timeline for the combined product. It is Q1 this year, not Q1 next year.
WellDoc and Voluntis, two companies with FDA-cleared, clinically validated platforms aimed at the management of Type 2 diabetes, have signed a commercial agreement to combine their technologies and offer joint products in the future.
“My thought is that a...
January 4, 2018
An analysis contracted by WellDoc found that the company’s digital therapeutic for Type 2 diabetes management could lead to an average savings of more than $250 per patient per month.
“The cost of a well-controlled diabetes patient will typically range in the $13,000 range [to] $20,000 annually. When you contrast that with the cost of a patient that doesn’t have diabetes, that number is typically...
January 4, 2017
WellDoc announced today a partnership with the American Association of Diabetes Educators (AADE), a professional membership organization of over 14,000 diabetes educators. WellDoc will incorporate educational content from AADE into its FDA-cleared, reimburseable BlueStar system for diabetes management.
"We were able to build a curriculum that will be able to be delivered in a contextually guided...
June 13, 2016
A number of pieces of interesting health tech news came out of the 76th Annual Scientific Sessions of the American Diabetes Association, held this weekend in New Orleans. Here’s a roundup of the highlights.
Updated 6/15/2016 to include some more news items.
IBM’s Medtronic partnership gets a name. Information has been trickling out about Medtronic’s collaboration with IBM Watson Health that was...
April 20, 2015
Two of the biggest medical journals in the world have taken up some big picture mobile health questions this week: How are patients to know which medical apps work out of the sea of available options, and should healthy patients be making use of mobile health apps and devices at all?
The first question is the subject of a recent article in the Journal of the American Medical Association, while...
January 10, 2014
Baltimore, Maryland-based WellDoc, one of the earliest and best known mobile health companies focused on diabetes management, has landed a $20 million round of investment that includes contributions from Merck Global Health Innovation Fund and Windham Venture Partners. The announcement marks WellDoc's first round of institutional money -- the company has long relied on angel investors and debt...